Carl Sandén Selected Research

Therapeutics

1/2022	Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.
10/2021	Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.
8/2015	Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl Sandén Research Topics

Disease

6	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023 - 09/2013
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 12/2016
2	Leukemia 03/2015 - 09/2013
1	Acute Promyelocytic Leukemia 10/2021
1	Blast Crisis (Blast Phase) 12/2016
1	Genetic Translocation (Chromosomal Translocation) 09/2013

Drug/Important Bio-Agent (IBA)

2	Tyrosine Kinase InhibitorsIBA 01/2018 - 12/2016
2	Therapeutic UsesIBA 12/2016 - 08/2015
2	AntibodiesIBA 12/2016 - 08/2015
1	NucleophosminIBA 11/2023
1	DiterpenesIBA 10/2021
1	MyostatinIBA 01/2020
1	CytokinesIBA 01/2020
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	Protein Isoforms (Isoforms)IBA 01/2017
1	Oncogene Proteins (Oncogene Protein)IBA 03/2015
1	Proteins (Proteins, Gene)FDA Link 09/2013
1	MTOR InhibitorsIBA 09/2013
1	Pyridinolcarbamate (P23)IBA 09/2013

Therapy/Procedure

3	Therapeutics 01/2022 - 08/2015